Liver cancer subtype test and immunotherapy study
Part of Cancer, Digestive system clinical trials.
This study looks at a 29-gene test to see if it can predict how well liver cancer responds to targeted therapy plus immunotherapy. If you have liver cancer and are getting this type of treatment, your stored tumor sample might help researchers learn more.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) through surgery or biopsy.
- You received targeted therapy combined with an immune checkpoint inhibitor after your tumor sample was taken.
- You have a frozen tumor sample from surgery (at least 3 grams) or a biopsy sample that can be used for gene testing.
- You have not had any local treatments like TACE or ablation within 4 weeks before or during your targeted-immunotherapy combination.
- You do not have another active cancer (except some cured skin, cervical, or thyroid cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
This study looks at how well a combination of liver-directed therapy and immunotherapy works for people with liver cancer that cannot be removed by surgery. It aims to find markers in your blood that might predict if the treatment will shrink the tumor enough to allow surgery later.
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
Hear when a new Primary Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.